Volume Buzz: Qihoo 360 Technology Co Ltd, Theravance Inc, NewLead Holdings Ltd, Star Scientific, Inc.(NASDAQ:STSI)

Lakeway, NY -- (SBWIRE) -- 02/27/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Qihoo 360 Technology Co Ltd (NYSE:QIHU) shares fell 4.95% to $29.97. The company announced that it will report its fourth quarter and full year 2012 financial results on Tuesday, March 5, 2013, after the close of U.S. markets. Qihoo 360's management will host a conference call to discuss the results at 7:30 p.m. Eastern Time on March 5, 2013 (8:30 a.m. Beijing time on March 6, 2013).

Additionally, the company recently announced that 360 Search will cooperate with Jike Search on a number of businesses. By cooperating with Jike Search, 360 Search will be able to access Jike’s search results for data from the State Food and Drug Administration (SFDA).

Is QIHU a Still a Buy after the Solid momentum? Let’s Find out Here

Theravance Inc (NASDAQ:THRX) shares fell 4.92% and closed at $20.48 in the last trading session. The company announced that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at The Boston Marriott Copley Place, Boston, MA on Tuesday, March 5, 2013 at 10:00 a.m. ET.

Is THRX a Strong Buying Opportunity After The Recent Slump? Find out Here

NewLead Holdings Ltd (NASDAQ:NEWL) shares declined 4.88% to $0.780. The company yesterday announced that the Company has signed an agreement to supply and deliver 1.48 million metric tons of steam coal to a third party buyer. The contract is expected to generate approximately $148.0 million in revenue over the period of the contract. NewLead also announced that the Company has entered into an agreement to extend previously announced mine acquisition agreements.

Should NEWL Buy After The Recent Movement? Let’s Find out Here

Star Scientific, Inc. (NASDAQ:STSI) shares declined 4.81% to $1.78. STSI’s stock was downgraded by Zacks analyst from an outperform rating to a neutral rating in a research note issued to investorson Jan. 31. The current target price on the stock is $2.60.
Additionally last month, the Company announces publication of the first peer-reviewed article examining the effects of anatabine in a mouse model of the debilitating autoimmune and neurodegenerative disease multiple sclerosis (MS).

Should STSI Buy After The Recent Movement? Let’s Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.